Protein variant generation by region shuffling
US-9593326-B2 · Mar 14, 2017 · US
Penicillin-G acylases
US11214786B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11214786-B2 |
| Application number | US-202016902001-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 15, 2020 |
| Priority date | May 5, 2016 |
| Publication date | Jan 4, 2022 |
| Grant date | Jan 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.
First claim
Opening claim text (preview).
What is claimed is: 1. An engineered polynucleotide encoding an engineered penicillin G acylase having a polypeptide sequence that is at least 95% identical to SEQ ID NO: 1220, wherein said penicillin G acylase comprises a leucine residue at position X2 as compared to the sequence of SEQ ID NO: 1220. 2. The engineered polynucleotide encoding the engineered penicillin G acylase of claim 1 , wherein said penicillin G acylase comprises SEQ ID NO: 1194. 3. The engineered polynucleotide encoding the engineered penicillin G acylase of claim 1 , wherein said penicillin G acylase is capable of producing phenyl acetate mono-protected or di-protected insulin. 4. The engineered polynucleotide encoding the engineered penicillin G acylase of claim 1 , wherein said penicillin G acylase is encoded by a polynucleotide sequence that is at least 95% identical to SEQ ID NO:1219. 5. The engineered polynucleotide encoding the engineered penicillin G acylase of claim 1 , wherein said penicillin G acylase comprises SEQ ID NO: 1220. 6. A vector comprising the engineered polynucleotide of claim 1 . 7. A host cell comprising the vector of claim 6 . 8. The host cell of claim 7 , wherein said host cell is a prokaryotic or eukaryotic cell. 9. The host cell of claim 8 , wherein said prokaryotic host cell is E. coli.
Assignees
Inventors
Classifications
Penicillin amidase (3.5.1.11), i.e. penicillin-amidohydrolase · CPC title
having a known sequence of two or more amino acids, e.g. glutathione · CPC title
- C12N9/84Primary
Penicillin amidase {(3.5.1.11)} · CPC title
Insulins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11214786B2 cover?
- The present invention provides engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.
- Who is the assignee on this patent?
- Codexis Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/84. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).